Novel assessment of leukocyte-rich platelet-rich plasma on functional and patient-reported outcomes in knee osteoarthritis: a pilot study - PubMed (original) (raw)

Novel assessment of leukocyte-rich platelet-rich plasma on functional and patient-reported outcomes in knee osteoarthritis: a pilot study

Prathap Jayaram et al. Regen Med. 2021 Sep.

Abstract

Background: Leukocyte-rich platelet-rich plasma (LR-PRP) has demonstrated to be beneficial for patients with knee osteoarthritis (KOA); however, reliable objective end points to accurately assess its therapeutic effects is lacking. Aim: To investigate the efficacy of LR-PRP as assessed by functional and patient-reported outcomes at early time points (6 weeks). Materials & methods: We conducted a prospective cohort study in 12 patients with diagnosed KOA (Kellgren Lawrence score of II-III), who underwent a single ultrasound-guided LR-PRP injection. Results: There was significant improvement in timed up and go, pain and quality of life scales and balance parameters. There were nonsignificant improvements in range of motion and gait parameters. Conclusion: LR-PRP demonstrates efficacy in meaningful end points for functional and patient-reported outcomes at early time points in patients with KOA.

Keywords: balance; functional outcomes; gait; knee injury and osteoarthritis outcome score 12; knee osteoarthritis; leukocyte-rich platelet-rich plasma; patient-reported outcomes; timed up and go; wearable sensor technology.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

This research was funded, in part, by the National Heart, Lung and Blood Institute (grant number: 5T32HL139430-02) and by the National Institute on Aging (grant number: 1R42AG060853-01). P Jayaram was supported by the HAE AHM Sea Rock Foundation and the Charlotte and Jamil Azzam Foundation. B Najafi and GE Kang have NIH funding (grant numbers: 1R42AG060853-01 and 5T32HL139430-02, respectively). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.. Leukocyte-rich platelet-rich plasma injection improves timed up and go duration at 6 weeks.

Mean values for TUG duration across all participants at baseline and 6 weeks. Error bars represent standard deviation. *Significant difference at post-LR-PRP compared with pre-LR-PRP (p < 0.05). LR-PRP: Leukocyte-rich platelet-rich plasma; TUG: Timed up and go.

Figure 2.. Leukocyte-rich platelet-rich plasma injection significantly improves KOOS-12 pain and quality of life at 6 weeks but does not significantly improve KOOS-12 function and visual analog score.

Mean values for (A) KOOS-12 pain, function and quality of life and (B) VAS across all participants at pre and post. Error bars represent standard deviation. *Significant differences at post-LR-PRP compared with pre-LR-PRP (p < 0.05). KOOS-12: Knee injury and osteoarthritis outcome score 12; LR-PRP: Leukocyte-rich platelet-rich plasma; QoL: Quality of life; VAS: Visual analog score.

Figure 3.. Correlation between KOOS-12 pain and timed up and go duration.

KOOS-12: Knee injury and osteoarthritis outcome score 12; TUG: Timed up and go.

Figure 4.. Leukocyte-rich platelet-rich plasma injection improves balance parameters.

Mean values for double-leg stance with (A) eyes open and (B) eyes closed conditions and (C) semi-tandem stance with eyes open and (D) eyes closed conditions. Error bars represent standard deviation. The unit for ML and AP COM sway is cm. The unit for COM sway area is cm2. The unit for ML and AP sway for the ankle and hip is degree. The unit for sway area in the hip and ankle is degree2. *Significant differences at post-LR-PRP compared with pre-LR-PRP (p < 0.05) . ‡Marginal differences at post-LR-PRP compared with pre-LR-PRP (p = 0.051). AP: Anterior–posterior; COM: Center of mass; LR-PRP: Leukocyte-rich platelet-rich plasma; ML: Medial–lateral.

References

1. Hootman JM, Helmick CG, Barbour KE, Theis KA, Boring MA. Updated projected prevalence of self-reported doctor-diagnosed arthritis and arthritis-attributable activity limitation among US adults, 2015–2040. Arthritis Rheum. 68(7), 1582–1587 (2016). -PMC -PubMed
1. McAlindon TE, Bannuru RR, Sullivan Met al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr. Cartil. 22(3), 363–388 (2014). -PubMed
1. McAlindon TE, LaValley MP, Harvey WFet al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA 317(19), 1967–1975 (2017). -PMC -PubMed
1. Jayaram P, Kennedy DJ, Yeh P, Dragoo J. Chondrotoxic effects of local anesthetics on human knee articular cartilage: a systematic review. PMR 11(4), 379–400 (2019). -PubMed
1. Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat. Rev. Rheumatol. 9(12), 721–730 (2013). -PubMed

Novel assessment of leukocyte-rich platelet-rich plasma on functional and patient-reported outcomes in knee osteoarthritis: a pilot study - PubMed (original) (raw)